NCT03263052 - Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

January 1, 2020

Study Completion Date

January 1, 2020

Conditions

Disorder Related to Renal Transplantation

Interventions

DRUG

Tacrolimus XR (Envarsus)

Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.

Trial Locations (1)

60612

University of Illinois at Chicago, Chicago